100 research outputs found
Editorial: CAR T-cells: novel therapeutic approaches in the new era of cancer immunotherapy
Immunotherapy has emerged as one of the most effective treatments capable of overcoming tumor resistance mechanisms due to its ability to modulate the patient’s immune response against cancer. Personalized anti-tumor therapy based on T cells engineered to express a cancer-specific chimeric antigen receptor (CAR) acts directly on the immune system of patients. Specifically, this therapy enhances the recognition of cancer cells by T lymphocytes, thus promoting their elimination. In this Research Topic several aspects of CAR T-cell therapy, with particular emphasis on novel findings aimed at ameliorating the effectiveness of CAR T-cell-based immunotherapy and reducing side effects, are described (Figure 1)
Diet, Inflammation, Body Composition and Type 2 Diabetes: Insights from epidemiological studies
With this thesis, I aim to further clarify how the factors diet, inflammation and body composition interact with each other and affect risk of type 2 diabetes from an epidemiological perspective
The role of positron-emission tomography in the diagnosis of giant cell arteritis
Abstract
Background: Giant cell arteritis (GCA) is an inflammatory disease of the larger vessels, typically affecting the temporal arteries,
but involvement of the carotid and thoracic arteries is not uncommon. Serious complications such as blindness can occur if the
disease is left untreated. Currently, the gold standard test for GCA is a temporal biopsy, but this invasive technique is not without
risks and frequently inaccurate. We investigate the use of 18-fluoro-desoxyglucose (18F-FDG) positron emission tomography
(PET) as a new diagnostic means in GCA.
Methods: We performed a literature search in the MEDLINE database for original research articles written in the English
language that discussed the use of PET in diagnosing GCA. After applying selection criteria, 9 articles were included for literature
review and 4 of these were incorporated in a meta-analysis.
Results: 18-FDG uptake in the extracranial arteries is correlated to the presence GCA within patients suspected for vasculitis. In
our meta-analysis we found the following results: sensitivity 85% (95% CI; 74-92%, I2=0.0%), specificity 91% (95% CI; 82-96%,
I2=31.2%), positive likelihood ratio 7.18 (95% CI; 3.43-15.06, I2 =10.1%) and negative likelihood ratio 0.19 (95% CI; 0.11-0.33,
I2= 0.0%).
Discussion: 18F-FDG-PET cannot replace temporal artery biopsy at the present time, because of its limited ability to visualise the
cranial arteries. However, PET may be provide valuable information when extracranial involvement is suspected, specifically in
biopsy-negative patients who are strongly suspected of having GCA
The future of affordable cancer immunotherapy
The treatment of cancer was revolutionized within the last two decades by utilizing the mechanism of the immune system against malignant tissue in so-called cancer immunotherapy. Two main developments boosted cancer immunotherapy: 1) the use of checkpoint inhibitors, which are characterized by a relatively high response rate mainly in solid tumors; however, at the cost of serious side effects, and 2) the use of chimeric antigen receptor (CAR)-T cells, which were shown to be very efficient in the treatment of hematologic malignancies, but failed to show high clinical effectiveness in solid tumors until now. In addition, active immunization against individual tumors is emerging, and the first products have reached clinical approval. These new treatment options are very cost-intensive and are not financially compensated by health insurance in many countries. Hence, strategies must be developed to make cancer immunotherapy affordable and to improve the cost-benefit ratio. In this review, we discuss the following strategies: 1) to leverage the antigenicity of “cold tumors” with affordable reagents, 2) to use microbiome-based products as markers or therapeutics, 3) to apply measures that make adoptive cell therapy (ACT) cheaper, e.g., the use of off-the-shelf products, 4) to use immunotherapies that offer cheaper platforms, such as RNA- or peptide-based vaccines and vaccines that use shared or common antigens instead of highly personal antigens, 5) to use a small set of predictive biomarkers instead of the “sequence everything” approach, and 6) to explore affordable immunohistochemistry markers that may direct individual therapies
Peptide fine specificity of anti-glycoprotein 100 TCR is preserved following transfer of engineered TCRalpha-Ăź genes into primary human T lymphocytes
Peptide fine specificity of anti-glycoprotein 100 TCR is preserved following transfer of engineered TCRalpha-Ăź genes into primary human T lymphocytes
Preclinical evaluation of NF-kappa B-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination
Background: Merkel cell carcinoma (MCC) is a rare but very aggressive skin tumor that develops after integration of a truncated form of the large T-antigen (truncLT) of the Merkel cell polyomavirus (MCV) into the host’s genome. Therapeutic vaccination with dendritic cells (DCs) loaded with tumor antigens is an active form of immunotherapy, which intends to direct the immune system towards tumors which express the respective vaccination antigens. Methods: Cytokine-matured monocyte-derived DCs of healthy donors and MCC patients were electroporated with mRNA encoding the truncLT. To permit major histocompatibility complex (MHC) class II next to class I presentation, we used an RNA construct in which the antigen was fused to a DCLamp sequence in addition to the unmodified antigen. To further improve their immunogenicity, the DCs were additionally activated by co-transfection with the constitutively active nuclear factor (NF)-κB activator caIKK. These DCs were used to stimulate autologous CD8 + T-cells or a mixture of CD4 + and CD8 + T-cells. Then the percentage of T-cells, specific for the truncLT, was quantified by interferon (IFN)γ ELISpot assays. Results: Both the truncLT and its DCLamp-fusion were detected within the DCs by flow cytometry, albeit the latter required blocking of the proteasome. The transfection with caIKK upregulated maturation markers and induced cytokine production. After 2–3 rounds of stimulation, the T-cells from 11 out of 13 healthy donors recognized the antigen. DCs without caIKK appeared in comparison less potent in inducing such responses. When using cells derived from MCC patients, we could induce responses for 3 out of 5 patients; however, here the caIKK-transfected DCs did not display their superiority. Conclusion: These results show that optimized DCs are able to induce MCV-antigen-specific T-cell responses. Therapeutic vaccination with such transfected DCs could direct the immune system against MCC
- …